Search

Your search keyword '"Di Maria, Gabriele"' showing total 34 results
Start Over Author "Di Maria, Gabriele"
34 results on '"Di Maria, Gabriele"'

1. Metabolic memory in diabetic foot syndrome (DFS): MICRO-RNAS, single nucleotide polymorphisms (SNPs) frequency and their relationship with indices of endothelial function and adipo-inflammatory dysfunction

Author

Del Cuore, Alessandro, Pipitone, Rosaria Maria, Casuccio, Alessandra, Mazzola, Marco Maria, Puleo, Maria Grazia, Pacinella, Gaetano, Riolo, Renata, Maida, Carlo, Di Chiara, Tiziana, Di Raimondo, Domenico, Zito, Rossella, Lupo, Giulia, Agnello, Luisa, Di Maria, Gabriele, Ciaccio, Marcello, Grimaudo, Stefania, and Tuttolomondo, Antonino

Published
2023
Full Text
View/download PDF

2. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease

Author

Pennisi, Grazia, Enea, Marco, Viganò, Mauro, Schepis, Filippo, de Ledinghen, Victor, Berzigotti, Annalisa, Wai-Sun Wong, Vincent, Fracanzani, Anna Ludovica, Sebastiani, Giada, Lara-Romero, Carmen, Bugianesi, Elisabetta, Svegliati-Baroni, Gianluca, Marra, Fabio, Aghemo, Alessio, Valenti, Luca, Calvaruso, Vincenza, Colecchia, Antonio, Di Maria, Gabriele, La Mantia, Claudia, Lin, Huapeng, Mendoza, Yuly P., Pugliese, Nicola, Ravaioli, Federico, Romero-Gomez, Manuel, Saltini, Dario, Craxì, Antonio, Di Marco, Vito, Cammà, Calogero, and Petta, Salvatore

Published
2023
Full Text
View/download PDF

3. THU-101 Non-invasive tests for ruling out high-risk esophageal varices in patients with primary biliary cholangitis based on the cholestasis degree

Author

Calvaruso, Vincenza, primary, Celsa, Ciro, additional, Cristoferi, Laura, additional, Scaravaglio, Miki, additional, Nofit, Eugenia, additional, Smith, Rachel, additional, Kaur, Senamjit, additional, Di Maria, Gabriele, additional, Capodicasa, Luigi, additional, Cadamuro, Luca, additional, Gerussi, Alessio, additional, Malinverno, Federica, additional, Lampertico, Pietro, additional, Cazzagon, Nora, additional, Marzioni, Marco, additional, Vespasiani-Gentilucci, Umberto, additional, Colapietro, Francesca, additional, Andreone, Pietro, additional, Lleo, Ana, additional, Rigamonti, Cristina, additional, Viganò, Mauro, additional, Giannini, Edoardo, additional, Russello, Maurizio, additional, Vanni, Ester, additional, Cerini, Federica, additional, Orlandini, Alessandra, additional, Brunetto, Maurizia, additional, Niro, Grazia Anna, additional, Vettori, Giovanni, additional, Castellaneta, Antonino, additional, Cardinale, Vincenzo, additional, Alvaro, Domenico, additional, Mega, Andrea, additional, Palitti, Valeria Pace, additional, Bellanti, Francesco, additional, Marco, Vito Di, additional, Mells, George, additional, Culver, Emma, additional, Invernizzi, Pietro, additional, Camma, Calogero, additional, and Carbone, Marco, additional

Published
2024
Full Text
View/download PDF

4. SAT-209-YI A Markov model unveiling the impact of Resmetirom on the natural history of MASLD patients with baseline significant or severe liver fibrosis

Author

Pennisi, Grazia, primary, Di Maria, Gabriele, additional, Enea, Marco, additional, Vaccaro, Marco, additional, Ciccioli, Carlo, additional, Celsa, Ciro, additional, Infantino, Giuseppe, additional, Tulone, Adele, additional, Di Marco, Vito, additional, Camma, Calogero, additional, and Petta, Salvatore, additional

Published
2024
Full Text
View/download PDF

5. Clinical outcomes of MAFLD versus NAFLD: A meta‐analysis of observational studies.

Author

Pennisi, Grazia, Infantino, Giuseppe, Celsa, Ciro, Di Maria, Gabriele, Enea, Marco, Vaccaro, Marco, Cannella, Roberto, Ciccioli, Carlo, La Mantia, Claudia, Mantovani, Alessandro, Mercurio, Francesco, Tilg, Herbert, Targher, Giovanni, Di Marco, Vito, Cammà, Calogero, and Petta, Salvatore

Subjects
NON-alcoholic fatty liver disease, CHRONIC kidney failure, CARDIOVASCULAR diseases, LIVER diseases, METABOLIC disorders
Abstract

Importance: The recent change in terminology from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction‐associated fatty liver disease (MAFLD) and metabolic dysfunction‐associated steatotic liver disease (MASLD) highlights the link between hepatic steatosis and metabolic dysfunction, taking out the stigmata of alcohol. Objective: We compared the effects of NAFLD and MAFLD definitions on the risk of overall and cardiovascular (CV) mortality, liver‐related events (LRE), nonfatal CV events (CVE), chronic kidney disease (CKD), and extra‐hepatic cancers (EHC). Data Sources and Study Selection: We systematically searched four large electronic databases for cohort studies (published through August 2023) that simultaneously used NAFLD and MAFLD definitions for examining the risk of mortality and adverse CV, renal, or oncological outcomes associated with both definitions. In total, 21 eligible cohort studies were identified. Meta‐analysis was performed using random‐effects modelling. Results: Compared with those with NAFLD, individuals with MAFLD had significantly higher rates of overall mortality (random‐effect OR 1.12, 95% CI 1.04–1.21, p =.004) and CV mortality (random‐effect OR 1.15, 95% CI 1.04–1.26, p =.004), and a marginal trend towards higher rates of developing CKD (random‐effect OR 1.06, 95% CI 1.00–1.12, p =.058) and EHC events (random‐effect OR 1.11, 95% CI 1.00–1.23, p =.052). We found no significant differences in the risk LREs and nonfatal CVE between MAFLD and NAFLD. Meta‐regression analyses identified male sex and metabolic comorbidities as the strongest risk factors related to the risk of adverse clinical outcomes in MAFLD compared to NAFLD. Conclusions and Relevance: Individuals with MAFLD have higher rates of overall and CV mortality and higher rates of developing CKD and EHC events than those with NAFLD, possibly due to the dysmetabolic risk profile related to MAFLD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg‐negative anti‐HBc‐positive patients? Meta‐analysis and decision curve analysis.

Author

Celsa, Ciro, Rizzo, Giacomo E. M., Di Maria, Gabriele, Enea, Marco, Vaccaro, Marco, Rancatore, Gabriele, Graceffa, Pietro, Falco, Giuseppe, Petta, Salvatore, Cabibbo, Giuseppe, Calvaruso, Vincenza, Craxì, Antonio, Cammà, Calogero, Di Marco, Vito, Rizzo, Chiara, Destro Castaniti, Giulia Maria, Di Stefano, Vincenzo, Madonia, Giorgio, Tilotta, Giovanna, and Agliastro, Giuseppe

Subjects
DISEASE risk factors, HEPATITIS B virus, DECISION making, CANCER patients, THERAPEUTICS
Abstract

Background and Aims: Patients with overt or occult hepatitis B virus (HBV) infection receiving immunosuppressive treatments have a wide risk of HBV reactivation (HBVr). We performed meta‐analysis with decision curve analyses (DCA) to estimate the risk of HBVr in HBsAg‐negative anti‐HBc‐positive patients naïve to nucleos(t)ide analogues (NAs) receiving immunosuppressive treatments. Approach and Results: Studies were identified through literature search until October 2022. Pooled estimates were obtained using random‐effects model. Subgroup analyses were performed according to underlying disease and immunosuppressive treatments. DCA was used to identify the threshold probability associated with the net benefit of antiviral prophylaxis in HBsAg‐negative anti‐HBc‐positive patients. We selected 68 studies (40 retrospective and 28 prospective), including 8034 patients with HBsAg negative anti‐HBc positive. HBVr was 4% (95% CI 3%–6%) in HBsAg‐negative anti‐HBc‐positive patients, with a significantly high heterogeneity (I2 69%; p <.01). The number‐needed‐to‐treat (NNT) by DCA ranged from 8 to 24 for chemotherapy plus rituximab, from 12 to 24 for targeted therapies in cancer patients and from 13 to 39 for immune‐mediated diseases. Net benefit was small for monoclonal antibodies. Conclusions: Our DCA in HBsAg‐negative anti‐HBc‐positive patients provided evidence that NA prophylaxis is strongly recommended in patients treated with chemotherapy combined with rituximab and could be appropriate in patients with cancer treated with targeted therapies and in patients with immune‐mediated diseases. Finally, in patients with cancer treated with monoclonal antibodies or with chemotherapy without rituximab, the net benefit is even lower. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. The Application of Large Language Models in Gastroenterology: A Review of the Literature.

Author

Maida, Marcello, Celsa, Ciro, Lau, Louis H. S., Ligresti, Dario, Baraldo, Stefano, Ramai, Daryl, Di Maria, Gabriele, Cannemi, Marco, Facciorusso, Antonio, and Cammà, Calogero

Subjects
MEDICAL education, HEALTH, ARTIFICIAL intelligence, EARLY detection of cancer, NATURAL language processing, INFORMATION resources, DECISION making, TREATMENT effectiveness, ENDOSCOPIC surgery, INFLAMMATORY bowel diseases, MATHEMATICAL models, COMMUNICATION, THEORY, INDIVIDUALIZED medicine, ACCESS to information, COLONOSCOPY, ENDOSCOPY
Abstract

Simple Summary: Large language models (LLMs) are revolutionizing the field of medicine, particularly in Gastroenterology, by improving access to information, diagnostics, treatment customization, and medical education. They analyze extensive medical data to enhance decision-making, patient outcomes, and educational tasks. While LLMs face challenges such as incomplete data, varying response accuracy, and reliance on specific input wording, they have shown promising results. However, their full integration into medical practice requires further research and regulation. Moreover, the successful integration of LLMs into medical practice necessitates customization to specific medical contexts and adherence to guidelines. This review focuses on the current evidence supporting the use of LLMs in Gastroenterology, emphasizing their potential and limitations. Large language models (LLMs) are transforming the medical landscape by enhancing access to information, diagnostics, treatment customization, and medical education, especially in areas like Gastroenterology. LLMs utilize extensive medical data to improve decision-making, leading to better patient outcomes and personalized medicine. These models are instrumental in interpreting medical literature and synthesizing patient data, facilitating real-time knowledge for physicians and supporting educational pursuits in medicine. Despite their potential, the complete integration of LLMs in real-life remains ongoing, particularly requiring further study and regulation. This review highlights the existing evidence supporting LLMs' use in Gastroenterology, addressing both their potential and limitations. Recent studies demonstrate LLMs' ability to answer questions from physicians and patients accurately. Specific applications in this field, such as colonoscopy, screening for colorectal cancer, and hepatobiliary and inflammatory bowel diseases, underscore LLMs' promise in improving the communication and understanding of complex medical scenarios. Moreover, the review discusses LLMs' efficacy in clinical contexts, providing guideline-based recommendations and supporting decision-making processes. Despite these advancements, challenges such as data completeness, reference suitability, variability in response accuracy, dependency on input phrasing, and a lack of patient-generated questions underscore limitations in reproducibility and generalizability. The effective integration of LLMs into medical practice demands refinement tailored to specific medical contexts and guidelines. Overall, while LLMs hold significant potential in transforming medical practice, ongoing development and contextual training are essential to fully realize their benefits. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Risk of liver-related events in metabolic dysfunction–associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria.

Author

Pennisi, Grazia, Enea, Marco, Romero-Gomez, Manuel, Bugianesi, Elisabetta, Wai-Sun Wong, Vincent, Fracanzani, Anna Ludovica, de Ledinghen, Victor, George, Jacob, Berzigotti, Annalisa, Viganò, Mauro, Sebastiani, Giada, Cannella, Roberto, Delamarre, Adèle, Di Maria, Gabriele, Lange, Naomi F., Tulone, Adele, Di Marco, Vito, Cammà, Calogero, and Petta, Salvatore

Published
2024
Full Text
View/download PDF

9. Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis.

Author

Celsa, Ciro, Cabibbo, Giuseppe, Pinato, David James, Di Maria, Gabriele, Enea, Marco, Vaccaro, Marco, Battaglia, Salvatore, Rizzo, Giacomo Emanuele Maria, Giuffrida, Paolo, Giacchetto, Carmelo Marco, Rancatore, Gabriele, Grassini, Maria Vittoria, and Cammà, Calogero

Subjects
IMMUNE checkpoint inhibitors, SURVIVAL rate, PROTEIN-tyrosine kinase inhibitors, OVERALL survival, ENDOTHELIAL growth factors, HEPATOCELLULAR carcinoma
Abstract

Background: Atezolizumab + bevacizumab represent the current standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC). However, direct comparison with other combination treatments including immune checkpoint inhibitors (ICI) + tyrosine kinase inhibitors (TKIs) are lacking. Objectives: This network meta-analysis (NMA) aims to indirectly compare the efficacy and the safety of first-line systemic therapies for unresectable advanced HCC. Method: A literature search of MEDLINE, Embase, and SCOPUS databases was conducted up to October 31, 2022. Phase 3 randomized controlled trials (RCTs) testing TKIs, including sorafenib and lenvatinib, or ICIs reporting overall survival (OS) and progression-free survival (PFS) were included. Individual survival data were extracted from OS and PFS curves to calculate restricted mean survival time. A Bayesian NMA was performed to compare treatments in terms of efficacy (15- and 30-month OS, 6-month PFS) and safety, represented by grade ≥3 (severe) adverse events (SAEs). The incremental safety-effectiveness ratio as measure of net health benefit was calculated as the difference in SAE probability divided by survival difference between the 2 most effective treatments. Results: Nine RCTs enrolling 6,600 patients were included. Atezolizumab plus bevacizumab showed the highest probability (88%) of achieving the 30-month OS landmark. Lenvatinib showed a probability of 86% of achieving best PFS outcomes. ICI monotherapies ranked as most tolerable. Atezolizumab plus bevacizumab showed the best net health benefit for OS, compared to durvalumab plus tremelimumab. When evaluating the net health benefit for PFS, at a willingness-to-risk threshold of 10% of SAEs for life-month gained, atezolizumab plus bevacizumab was favoured in 78% of cases, while at threshold of 30% of SAEs for life-month gained, lenvatinib was favoured in 76% of cases. Conclusions: Atezolizumab plus bevacizumab is the best treatment in terms of net benefit and therefore it should be recommended as standard of care. Compared to atezolizumab plus bevacizumab, lenvatinib monotherapy had the best net benefit for PFS when physicians and patients are available to accept a higher risk of toxicity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Risk of liver-related events in metabolic dysfunction–associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria

Author

Pennisi, Grazia, primary, Enea, Marco, additional, Romero-Gomez, Manuel, additional, Bugianesi, Elisabetta, additional, Wai-Sun Wong, Vincent, additional, Fracanzani, Anna Ludovica, additional, de Ledinghen, Victor, additional, George, Jacob, additional, Berzigotti, Annalisa, additional, Viganò, Mauro, additional, Sebastiani, Giada, additional, Cannella, Roberto, additional, Delamarre, Adèle, additional, Di Maria, Gabriele, additional, Lange, Naomi F., additional, Tulone, Adele, additional, Di Marco, Vito, additional, Cammà, Calogero, additional, and Petta, Salvatore, additional

Published
2023
Full Text
View/download PDF

11. Red and golden tomato administration improves fat diet-induced hepatic steatosis in rats by modulating HNF4α, Lepr, and GK expression

Author

Pipitone, Rosaria Maria, primary, Zito, Rossella, additional, Gambino, Giuditta, additional, Di Maria, Gabriele, additional, Javed, Ayesha, additional, Lupo, Giulia, additional, Giglia, Giuseppe, additional, Sardo, Pierangelo, additional, Ferraro, Giuseppe, additional, Rappa, Francesca, additional, Carlisi, Daniela, additional, Di Majo, Danila, additional, and Grimaudo, Stefania, additional

Published
2023
Full Text
View/download PDF

12. Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis

Author

Celsa, Ciro, primary, Cabibbo, Giuseppe, additional, Pinato, David James, additional, Di Maria, Gabriele, additional, Enea, Marco, additional, Vaccaro, Marco, additional, Battaglia, Salvatore, additional, Rizzo, Giacomo Emanuele Maria, additional, Giuffrida, Paolo, additional, Giacchetto, Carmelo Marco, additional, Rancatore, Gabriele, additional, Grassini, Maria Vittoria, additional, and Cammà, Calogero, additional

Published
2023
Full Text
View/download PDF

13. Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis

Author

Celsa, Ciro, primary, Cabibbo, Giuseppe, additional, Di Maria, Gabriele, additional, Vaccaro, Marco, additional, Battaglia, Salvatore, additional, Maria Rizzo, Giacomo Emanuele, additional, Ciccia, Roberta, additional, Grova, Alessandro, additional, Salvato, Mauro, additional, Giuffrida, Paolo, additional, Giacchetto, Marco, additional, Rancatore, Gabriele, additional, Grassini, Maria Vittoria, additional, Antonucci, Michela, additional, Morana, Piera, additional, Enea, Marco, additional, and Camma, Calogero, additional

Published
2023
Full Text
View/download PDF

14. Programmed cell death 1 genetic variant and liver damage in non-alcoholic fatty liver disease

Author

Pennisi, Grazia, primary, Pipitone, Rosaria Maria, additional, Malvestiti, Francesco, additional, Jamialahmadi, Oveis, additional, Dongiovanni, Paola, additional, Bertolazzi, Giorgio, additional, Pihlajamaki, Jussi, additional, Yki-Järvinen, Hannele, additional, Gentilucci, Umberto Vespasiani, additional, Tavaglione, Federica, additional, Maurotti, Samantha, additional, Bianco, Cristiana, additional, Di Maria, Gabriele, additional, Enea, Marco, additional, Fracanzani, Anna Ludovica, additional, Kärjä, Vesa, additional, Lupo, Giulia, additional, Männistö, Ville, additional, Meroni, Marica, additional, Piciotti, Roberto, additional, Qadri, Sami, additional, Zito, Rossella, additional, Craxi, Antonio, additional, Di Marco, Vito, additional, Camma, Calogero, additional, Tripodo, Claudio, additional, Valenti, Luca, additional, Romeo, Stefano, additional, Petta, Salvatore, additional, and Grimaudo, Stefania, additional

Published
2023
Full Text
View/download PDF

15. Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced non-alcoholic fatty liver disease

Author

Pennisi, Grazia, primary, Enea, Marco, additional, Viganò, Mauro, additional, Schepis, Filippo, additional, de Lédinghen, Victor, additional, Berzigotti, Annalisa, additional, Wong, Vincent Wai-Sun, additional, Fracanzani, Anna Ludovica, additional, Sebastiani, Giada, additional, Gomez, Manuel Romero, additional, Bugianesi, Elisabetta, additional, Svegliati-Baroni, Gianluca, additional, Marra, Fabio, additional, Aghemo, Alessio, additional, Valenti, Luca, additional, Calvaruso, Vincenza, additional, Colecchia, Antonio, additional, Di Maria, Gabriele, additional, La Mantia, Claudia, additional, Lin, Huapeng, additional, Mendoza, Yuly, additional, Pugliese, Nicola, additional, Ravaioli, Federico, additional, Lara-Romero, Carmen, additional, Saltini, Dario, additional, Craxi, Antonio, additional, Di Marco, Vito, additional, Camma, Calogero, additional, and Petta, Salvatore, additional

Published
2023
Full Text
View/download PDF

16. RESIST criteria accurately rule-out high-risk esophageal varices in patients with primary biliary cholangitis and compensated advanced chronic liver disease

Author

Calvaruso, Vincenza, primary, Celsa, Ciro, additional, Cristoferi, Laura, additional, Scaravaglio, Miki, additional, Capodicasa, Luigi, additional, Cadamuro, Luca, additional, Di Maria, Gabriele, additional, Di Marco, Vito, additional, Gerussi, Alessio, additional, Malinverno, Federica, additional, Lampertico, Pietro, additional, Cazzagon, Nora, additional, Marzioni, Marco, additional, Gentilucci, Umberto Vespasiani, additional, Andreone, Pietro, additional, Lleo, Ana, additional, Rigamonti, Cristina, additional, Giannini, Edoardo Giovanni, additional, Russello, Maurizio, additional, Vanni, Ester, additional, Cerini, Federica, additional, Missale, Gabriele, additional, Brunetto, Maurizia, additional, Niro, Grazia, additional, Vettori, Giovanni, additional, Castellaneta, Antonino, additional, Alvaro, Domenico, additional, Palitti, Valeria Pace, additional, Bellanti, Francesco, additional, Invernizzi, Pietro, additional, Camma, Calogero, additional, and Carbone, Marco, additional

Published
2023
Full Text
View/download PDF

17. Risk factors for viral reactivation in patients with overt or occult HepatitisB Virus infection receiving immunosuppressive treatments: a systematic review and meta-analysis

Author

Celsa, Ciro, primary, Maria Rizzo, Giacomo Emanuele, additional, Rancatore, Gabriele, additional, Graceffa, Pietro, additional, Falco, Giuseppe, additional, Di Maria, Gabriele, additional, Vaccaro, Marco, additional, Enea, Marco, additional, Calvaruso, Vincenza, additional, Camma, Calogero, additional, and Di Marco, Vito, additional

Published
2023
Full Text
View/download PDF

18. Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study

Author

Riggio, Oliviero, primary, Celsa, Ciro, additional, Calvaruso, Vincenza, additional, Merli, Manuela, additional, Caraceni, Paolo, additional, Montagnese, Sara, additional, Mora, Vincenzina, additional, Milana, Martina, additional, Saracco, Giorgio Maria, additional, Raimondo, Giovanni, additional, Benedetti, Antonio, additional, Burra, Patrizia, additional, Sacco, Rodolfo, additional, Persico, Marcello, additional, Schepis, Filippo, additional, Villa, Erica, additional, Colecchia, Antonio, additional, Fagiuoli, Stefano, additional, Pirisi, Mario, additional, Barone, Michele, additional, Azzaroli, Francesco, additional, Soardo, Giorgio, additional, Russello, Maurizio, additional, Morisco, Filomena, additional, Labanca, Sara, additional, Fracanzani, Anna Ludovica, additional, Pietrangelo, Antonello, additional, Di Maria, Gabriele, additional, Nardelli, Silvia, additional, Ridola, Lorenzo, additional, Gasbarrini, Antonio, additional, and Cammà, Calogero, additional

Published
2023
Full Text
View/download PDF

19. Red and Golden Tomato Administration Improves Fat Di-Et-Induced Hepatic Steatosis in Rats by Modulating HNF4, Lepr and GK Expression

Author

Pipitone, Rosaria Maria, primary, Zito, Rossella, additional, Gambino, Giuditta, additional, Di Maria, Gabriele, additional, Javed, Ayesha, additional, Lupo, Giulia, additional, Giglia, Giuseppe, additional, Sardo, Pierangelo, additional, Ferraro, Giuseppe, additional, Rappa, Francesca, additional, Carlisi, Daniela, additional, Di Majo, Danila, additional, and Grimaudo, Stefania, additional

Published
2023
Full Text
View/download PDF

20. Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease

Author

Pipitone, Rosaria M., primary, Malvestiti, Francesco, additional, Pennisi, Grazia, additional, Jamialahmadi, Oveis, additional, Dongiovanni, Paola, additional, Bertolazzi, Giorgio, additional, Pihlajamäki, Jussi, additional, Yki‐Järvinen, Hannele, additional, Vespasiani‐Gentilucci, Umberto, additional, Tavaglione, Federica, additional, Maurotti, Samantha, additional, Bianco, Cristiana, additional, Di Maria, Gabriele, additional, Enea, Marco, additional, Fracanzani, Anna L., additional, Kärjä, Vesa, additional, Lupo, Giulia, additional, Männistö, Ville, additional, Meroni, Marica, additional, Piciotti, Roberto, additional, Qadri, Sami, additional, Zito, Rossella, additional, Craxì, Antonio, additional, Di Marco, Vito, additional, Cammà, Calogero, additional, Tripodo, Claudio, additional, Valenti, Luca, additional, Romeo, Stefano, additional, Petta, Salvatore, additional, and Grimaudo, Stefania, additional

Published
2023
Full Text
View/download PDF

21. Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study

Author

Riggio, Oliviero, Celsa, Ciro, Calvaruso, Vincenza, Merli, Manuela, Caraceni, Paolo, Montagnese, Sara, Mora, Vincenzina, Milana, Martina, Saracco, Giorgio Maria, Raimondo, Giovanni, Benedetti, Antonio, Burra, Patrizia, Sacco, Rodolfo, Persico, Marcello, Schepis, Filippo, Villa, Erica, Colecchia, Antonio, Fagiuoli, Stefano, Pirisi, Mario, Barone, Michele, Azzaroli, Francesco, Soardo, Giorgio, Russello, Maurizio, Morisco, Filomena, Labanca, Sara, Fracanzani, Anna Ludovica, Pietrangelo, Antonello, Di Maria, Gabriele, Nardelli, Silvia, Ridola, Lorenzo, Gasbarrini, Antonio, Cammà, Calogero, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Riggio, Oliviero, Celsa, Ciro, Calvaruso, Vincenza, Merli, Manuela, Caraceni, Paolo, Montagnese, Sara, Mora, Vincenzina, Milana, Martina, Saracco, Giorgio Maria, Raimondo, Giovanni, Benedetti, Antonio, Burra, Patrizia, Sacco, Rodolfo, Persico, Marcello, Schepis, Filippo, Villa, Erica, Colecchia, Antonio, Fagiuoli, Stefano, Pirisi, Mario, Barone, Michele, Azzaroli, Francesco, Soardo, Giorgio, Russello, Maurizio, Morisco, Filomena, Labanca, Sara, Fracanzani, Anna Ludovica, Pietrangelo, Antonello, Di Maria, Gabriele, Nardelli, Silvia, Ridola, Lorenzo, Gasbarrini, Antonio, Cammà, Calogero, and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)

Abstract

IntroductionHepatic encephalopathy (HE) affects the survival and quality of life of patients with cirrhosis. However, longitudinal data on the clinical course after hospitalization for HE are lacking. The aim was to estimate mortality and risk for hospital readmission of cirrhotic patients hospitalized for HE. MethodsWe prospectively enrolled 112 consecutive cirrhotic patients hospitalized for HE (HE group) at 25 Italian referral centers. A cohort of 256 patients hospitalized for decompensated cirrhosis without HE served as controls (no HE group). After hospitalization for HE, patients were followed-up for 12 months until death or liver transplant (LT). ResultsDuring follow-up, 34 patients (30.4%) died and 15 patients (13.4%) underwent LT in the HE group, while 60 patients (23.4%) died and 50 patients (19.5%) underwent LT in the no HE group. In the whole cohort, age (HR 1.03, 95% CI 1.01-1.06), HE (HR 1.67, 95% CI 1.08-2.56), ascites (HR 2.56, 95% CI 1.55-4.23), and sodium levels (HR 0.94, 95% CI 0.90-0.99) were significant risk factors for mortality. In the HE group, ascites (HR 5.07, 95% CI 1.39-18.49) and BMI (HR 0.86, 95% CI 0.75-0.98) were risk factors for mortality, and HE recurrence was the first cause of hospital readmission. ConclusionIn patients hospitalized for decompensated cirrhosis, HE is an independent risk factor for mortality and the most common cause of hospital readmission compared with other decompensation events. Patients hospitalized for HE should be evaluated as candidates for LT.

Published
2023

22. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease

Author

Ministero dell'Istruzione e del Merito, Fonds de Recherche du Québec, Pennisi, Grazia, Enea, Marco, Viganò, Mauro, Schepis, Filippo, Ledinghen, Victor de, Berzigotti, Annalisa, Wai-Sun Wong, Vincent, Fracanzani, Anna Ludovica, Sebastiani, Giada, Lara-Romero, Carmen, Bugianesi, Elisabetta, Svegliati-Baroni, Gianluca, Marra, Fabio, Aghemo, Alessio, Valenti, Luca, Calvaruso, Vincenza, Colecchia, Antonio, Di Maria, Gabriele, La Mantia, Claudia, Lin, Huapeng, Mendoza, Yuly, Pugliese, Nicola, Ravaioli, Federico, Romero-Gómez, Manuel, Saltini, Dario, Craxi, Antonio, Di Marco, Vito, Cammà, Calogero, Petta, Salvatore, Ministero dell'Istruzione e del Merito, Fonds de Recherche du Québec, Pennisi, Grazia, Enea, Marco, Viganò, Mauro, Schepis, Filippo, Ledinghen, Victor de, Berzigotti, Annalisa, Wai-Sun Wong, Vincent, Fracanzani, Anna Ludovica, Sebastiani, Giada, Lara-Romero, Carmen, Bugianesi, Elisabetta, Svegliati-Baroni, Gianluca, Marra, Fabio, Aghemo, Alessio, Valenti, Luca, Calvaruso, Vincenza, Colecchia, Antonio, Di Maria, Gabriele, La Mantia, Claudia, Lin, Huapeng, Mendoza, Yuly, Pugliese, Nicola, Ravaioli, Federico, Romero-Gómez, Manuel, Saltini, Dario, Craxi, Antonio, Di Marco, Vito, Cammà, Calogero, and Petta, Salvatore

Abstract

[Background & Aims] We aimed to evaluate the impact of oesophageal varices (OV) and their evolution on the risk of complications of compensated advanced chronic liver disease (cACLD) caused by non-alcoholic fatty liver disease (NAFLD). We also assessed the accuracy of non-invasive scores for predicting the development of complications and for identifying patients at low risk of high-risk OV., [Methods] We performed a retrospective assessment of 629 patients with NAFLD-related cACLD who had baseline and follow-up oesophagogastroduodenoscopy and clinical follow-up to record decompensation, portal vein thrombosis (PVT), and hepatocellular carcinoma., [Results] Small and large OV were observed at baseline in 30 and 15.9% of patients, respectively. The 4-year incidence of OV from absence at baseline, and that of progression from small to large OV were 16.3 and 22.4%, respectively. Diabetes and a ≥5% increase in BMI were associated with OV progression. Multivariate Cox regression revealed that small (hazard ratio [HR] 2.24, 95% CI 1.47–3.41) and large (HR 3.86, 95% CI 2.34–6.39) OV were independently associated with decompensation. When considering OV status and trajectories, small (HR 2.65, 95% CI 1.39–5.05) and large (HR 4.90, 95% CI 2.49–9.63) OV at baseline and/or follow-up were independently associated with decompensation compared with the absence of OV at baseline and/or follow-up. The presence of either small (HR 2.8, 95% CI 1.16–6.74) or large (HR 5.29, 95% CI 1.96–14.2) OV was also independently associated with incident PVT., [Conclusion] In NAFLD-related cACLD, the presence, severity, and evolution of OV stratify the risk of developing decompensation and PVT., [Impact and implications] Portal hypertension is the main driver of liver decompensation in chronic liver diseases, and its non-invasive markers can help risk prediction. The presence, severity, and progression of oesophageal varices stratify the risk of complications of non-alcoholic fatty liver disease. Easily obtainable laboratory values and liver stiffness measurement can identify patients at low risk for whom endoscopy may be withheld, and can also stratify the risk of liver-related complications.

Published
2023

23. Curcumin and Andrographolide Co-Administration Safely Prevent Steatosis Induction and ROS Production in HepG2 Cell Line

Author

Pipitone, Rosaria Maria, primary, Zito, Rossella, additional, Lupo, Giulia, additional, Javed, Ayesha, additional, La Mantia, Claudia, additional, Di Maria, Gabriele, additional, Pratelli, Giovanni, additional, Di Salvo, Francesca, additional, Fontana, Simona, additional, Pucci, Marzia, additional, Carlisi, Daniela, additional, and Grimaudo, Stefania, additional

Published
2023
Full Text
View/download PDF

24. Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model

Author

Vizzutti, Francesco, primary, Celsa, Ciro, additional, Calvaruso, Vincenza, additional, Enea, Marco, additional, Battaglia, Salvatore, additional, Turco, Laura, additional, Senzolo, Marco, additional, Nardelli, Silvia, additional, Miraglia, Roberto, additional, Roccarina, Davide, additional, Campani, Claudia, additional, Saltini, Dario, additional, Caporali, Cristian, additional, Indulti, Federica, additional, Gitto, Stefano, additional, Zanetto, Alberto, additional, Di Maria, Gabriele, additional, Bianchini, Marcello, additional, Pecchini, Maddalena, additional, Aspite, Silvia, additional, Di Bonaventura, Chiara, additional, Citone, Michele, additional, Guasconi, Tomas, additional, Di Benedetto, Fabrizio, additional, Arena, Umberto, additional, Fanelli, Fabrizio, additional, Maruzzelli, Luigi, additional, Riggio, Oliviero, additional, Burra, Patrizia, additional, Colecchia, Antonio, additional, Villa, Erica, additional, Marra, Fabio, additional, Cammà, Calogero, additional, and Schepis, Filippo, additional

Published
2022
Full Text
View/download PDF

25. Mortality after transjugular intrahepatic portosystemic shunt in older adult cirrhotic patients: a validated prediction model

Author

Vizzutti, Francesco, Celsa, Ciro, Calvaruso, Vincenza, Enea, Marco, Battaglia, Salvatore, Turco, Laura, Senzolo, Marco, Nardelli, Silvia, Miraglia, Roberto, Roccarina, Davide, Campani, Claudia, Saltini, Dario, Caporali, Cristian, Indulti, Federica, Gitto, Stefano, Zanetto, Alberto, Di Maria, Gabriele, Bianchini, Marcello, Pecchini, Maddalena, Aspite, Silvia, Di Bonaventura, Chiara, Citone, Michele, Guasconi, Tomas, Di Benedetto, Fabrizio, Arena, Umberto, Fanelli, Fabrizio, Maruzzelli, Luigi, Riggio, Oliviero, Burra, Patrizia, Colecchia, Antonio, Villa, Erica, Marra, Fabio, Cammà, Calogero, and Schepis, Filippo

Published
2022

26. Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model.

Author

Vizzutti, Francesco, Celsa, Ciro, Calvaruso, Vincenza, Enea, Marco, Battaglia, Salvatore, Turco, Laura, Senzolo, Marco, Nardelli, Silvia, Miraglia, Roberto, Roccarina, Davide, Campani, Claudia, Saltini, Dario, Caporali, Cristian, Indulti, Federica, Gitto, Stefano, Zanetto, Alberto, Di Maria, Gabriele, Bianchini, Marcello, Pecchini, Maddalena, and Aspite, Silvia

Published
2023
Full Text
View/download PDF

28. WED-549 - Programmed cell death 1 genetic variant and liver damage in non-alcoholic fatty liver disease

Author

Pennisi, Grazia, Pipitone, Rosaria Maria, Malvestiti, Francesco, Jamialahmadi, Oveis, Dongiovanni, Paola, Bertolazzi, Giorgio, Pihlajamaki, Jussi, Yki-Järvinen, Hannele, Gentilucci, Umberto Vespasiani, Tavaglione, Federica, Maurotti, Samantha, Bianco, Cristiana, Di Maria, Gabriele, Enea, Marco, Fracanzani, Anna Ludovica, Kärjä, Vesa, Lupo, Giulia, Männistö, Ville, Meroni, Marica, Piciotti, Roberto, Qadri, Sami, Zito, Rossella, Craxi, Antonio, Di Marco, Vito, Camma, Calogero, Tripodo, Claudio, Valenti, Luca, Romeo, Stefano, Petta, Salvatore, and Grimaudo, Stefania

Published
2023
Full Text
View/download PDF

29. THU-421 - Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced non-alcoholic fatty liver disease

Author

Pennisi, Grazia, Enea, Marco, Viganò, Mauro, Schepis, Filippo, de Lédinghen, Victor, Berzigotti, Annalisa, Wong, Vincent Wai-Sun, Fracanzani, Anna Ludovica, Sebastiani, Giada, Gomez, Manuel Romero, Bugianesi, Elisabetta, Svegliati-Baroni, Gianluca, Marra, Fabio, Aghemo, Alessio, Valenti, Luca, Calvaruso, Vincenza, Colecchia, Antonio, Di Maria, Gabriele, La Mantia, Claudia, Lin, Huapeng, Mendoza, Yuly, Pugliese, Nicola, Ravaioli, Federico, Lara-Romero, Carmen, Saltini, Dario, Craxi, Antonio, Di Marco, Vito, Camma, Calogero, and Petta, Salvatore

Published
2023
Full Text
View/download PDF

30. THU-144 - Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis

Author

Celsa, Ciro, Cabibbo, Giuseppe, Di Maria, Gabriele, Vaccaro, Marco, Battaglia, Salvatore, Maria Rizzo, Giacomo Emanuele, Ciccia, Roberta, Grova, Alessandro, Salvato, Mauro, Giuffrida, Paolo, Giacchetto, Marco, Rancatore, Gabriele, Grassini, Maria Vittoria, Antonucci, Michela, Morana, Piera, Enea, Marco, and Camma, Calogero

Published
2023
Full Text
View/download PDF

31. WED-260 - RESIST criteria accurately rule-out high-risk esophageal varices in patients with primary biliary cholangitis and compensated advanced chronic liver disease

Author

Calvaruso, Vincenza, Celsa, Ciro, Cristoferi, Laura, Scaravaglio, Miki, Capodicasa, Luigi, Cadamuro, Luca, Di Maria, Gabriele, Di Marco, Vito, Gerussi, Alessio, Malinverno, Federica, Lampertico, Pietro, Cazzagon, Nora, Marzioni, Marco, Gentilucci, Umberto Vespasiani, Andreone, Pietro, Lleo, Ana, Rigamonti, Cristina, Giannini, Edoardo Giovanni, Russello, Maurizio, Vanni, Ester, Cerini, Federica, Missale, Gabriele, Brunetto, Maurizia, Niro, Grazia, Vettori, Giovanni, Castellaneta, Antonino, Alvaro, Domenico, Palitti, Valeria Pace, Bellanti, Francesco, Invernizzi, Pietro, Camma, Calogero, and Carbone, Marco

Published
2023
Full Text
View/download PDF

32. Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model

Author

Francesco Vizzutti, Ciro Celsa, Vincenza Calvaruso, Marco Enea, Salvatore Battaglia, Laura Turco, Marco Senzolo, Silvia Nardelli, Roberto Miraglia, Davide Roccarina, Claudia Campani, Dario Saltini, Cristian Caporali, Federica Indulti, Stefano Gitto, Alberto Zanetto, Gabriele Di Maria, Marcello Bianchini, Maddalena Pecchini, Silvia Aspite, Chiara Di Bonaventura, Michele Citone, Tomas Guasconi, Fabrizio Di Benedetto, Umberto Arena, Fabrizio Fanelli, Luigi Maruzzelli, Oliviero Riggio, Patrizia Burra, Antonio Colecchia, Erica Villa, Fabio Marra, Calogero Cammà, Filippo Schepis, Vizzutti, Francesco, Celsa, Ciro, Calvaruso, Vincenza, Enea, Marco, Battaglia, Salvatore, Turco, Laura, Senzolo, Marco, Nardelli, Silvia, Miraglia, Roberto, Roccarina, Davide, Campani, Claudia, Saltini, Dario, Caporali, Cristian, Indulti, Federica, Gitto, Stefano, Zanetto, Alberto, Di Maria, Gabriele, Bianchini, Marcello, Pecchini, Maddalena, Aspite, Silvia, Di Bonaventura, Chiara, Citone, Michele, Guasconi, Toma, Di Benedetto, Fabrizio, Arena, Umberto, Fanelli, Fabrizio, Maruzzelli, Luigi, Riggio, Oliviero, Burra, Patrizia, Colecchia, Antonio, Villa, Erica, Marra, Fabio, Camma, Calogero, and Schepis, Filippo

Subjects
Hepatology, TIPS, elderly, cirrhosi
Abstract

Background and Aims Implantation of a transjugular intrahepatic portosystemic shunt (TIPS) improves survival in patients with cirrhosis with refractory ascites and portal hypertensive bleeding. However, the indication for TIPS in older adult patients (greater than or equal to 70 years) is debated, and a specific prediction model developed in this particular setting is lacking. The aim of this study was to develop and validate a multivariable model for an accurate prediction of mortality in older adults. Approach and Results We prospectively enrolled 411 consecutive patients observed at four referral centers with de novo TIPS implantation for refractory ascites or secondary prophylaxis of variceal bleeding (derivation cohort) and an external cohort of 415 patients with similar indications for TIPS (validation cohort). Older adult patients in the two cohorts were 99 and 76, respectively. A cause-specific Cox competing risks model was used to predict liver-related mortality, with orthotopic liver transplant and death for extrahepatic causes as competing events. Age, alcoholic etiology, creatinine levels, and international normalized ratio in the overall cohort, and creatinine and sodium levels in older adults were independent risk factors for liver-related death by multivariable analysis. Conclusions After TIPS implantation, mortality is increased by aging, but TIPS placement should not be precluded in patients older than 70 years. In older adults, creatinine and sodium levels are useful predictors for decision making. Further efforts to update the prediction model with larger sample size are warranted.

Published
2022

33. Curcumin and Andrographolide Co-Administration Safely Prevent Steatosis Induction and ROS Production in HepG2 Cell Line

Author

Rosaria Maria Pipitone, Rossella Zito, Giulia Lupo, Ayesha Javed, Claudia La Mantia, Gabriele Di Maria, Giovanni Pratelli, Francesca Di Salvo, Simona Fontana, Marzia Pucci, Daniela Carlisi, Stefania Grimaudo, Pipitone, Rosaria Maria, Zito, Rossella, Lupo, Giulia, Javed, Ayesha, La Mantia, Claudia, Di Maria, Gabriele, Pratelli, Giovanni, Di Salvo, Francesca, Fontana, Simona, Pucci, Marzia, Carlisi, Daniela, and Grimaudo, Stefania

Subjects
lipid droplets, Organic Chemistry, andrographolide, Pharmaceutical Science, GK, ROS, Analytical Chemistry, liver steatosis, Settore BIO/13 - Biologia Applicata, Chemistry (miscellaneous), NAFLD, Drug Discovery, PPARGC1A, Molecular Medicine, FABP1, curcumin, Physical and Theoretical Chemistry
Abstract

Non-alcoholic fatty liver disease (NAFLD) is an emerging chronic liver disease worldwide. Curcumin and andrographolide are famous for improving hepatic functions, being able to reverse oxidative stress and release pro-inflammatory cytokines, and they are implicated in hepatic stellate cell activation and in liver fibrosis development. Thus, we tested curcumin and andrographolide separately and in combination to determine their effect on triglyceride accumulation and ROS production, identifying the differential expression of genes involved in fatty liver and oxidative stress development. In vitro steatosis was induced in HepG2 cells and the protective effect of curcumin, andrographolide, and their combination was observed evaluating cell viability, lipid and triglyceride content, ROS levels, and microarray differential gene expression. Curcumin, andrographolide, and their association were effective in reducing steatosis, triglyceride content, and ROS stress, downregulating the genes involved in lipid accumulation. Moreover, the treatments were able to protect the cytotoxic effect of steatosis, promoting the expression of survival and anti-inflammatory genes. The present study showed that the association of curcumin and andrographolide could be used as a therapeutic approach to counter high lipid content and ROS levels in steatosis liver, avoiding the possible hepatotoxic effect of curcumin. Furthermore, this study improved our understanding of the antisteatosis and hepatoprotective properties of a curcumin and andrographolide combination.

Published
2023
Full Text
View/download PDF

34. Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease

Author

Rosaria M. Pipitone, Francesco Malvestiti, Grazia Pennisi, Oveis Jamialahmadi, Paola Dongiovanni, Giorgio Bertolazzi, Jussi Pihlajamäki, Hannele Yki‐Järvinen, Umberto Vespasiani‐Gentilucci, Federica Tavaglione, Samantha Maurotti, Cristiana Bianco, Gabriele Di Maria, Marco Enea, Anna L. Fracanzani, Vesa Kärjä, Giulia Lupo, Ville Männistö, Marica Meroni, Roberto Piciotti, Sami Qadri, Rossella Zito, Antonio Craxì, Vito Di Marco, Calogero Cammà, Claudio Tripodo, Luca Valenti, Stefano Romeo, Salvatore Petta, Stefania Grimaudo, Pipitone, Rosaria M, Malvestiti, Francesco, Pennisi, Grazia, Jamialahmadi, Ovei, Dongiovanni, Paola, Bertolazzi, Giorgio, Pihlajamäki, Jussi, Yki-Järvinen, Hannele, Vespasiani-Gentilucci, Umberto, Tavaglione, Federica, Maurotti, Samantha, Bianco, Cristiana, Di Maria, Gabriele, Enea, Marco, Fracanzani, Anna L, Kärjä, Vesa, Lupo, Giulia, Männistö, Ville, Meroni, Marica, Piciotti, Roberto, Qadri, Sami, Zito, Rossella, Craxì, Antonio, Di Marco, Vito, Cammà, Calogero, Tripodo, Claudio, Valenti, Luca, Romeo, Stefano, Petta, Salvatore, and Grimaudo, Stefania

Subjects
Settore MED/12 - Gastroenterologia, Hepatology, Settore BIO/13 - Biologia Applicata, Gastroenterology, CXCR6, NAFLD, NASH, PDCD1, checkpoint inhibitors
Abstract

Background and aims: Programmed cell death 1/programmed cell death-ligand 1 (PD-1/PDL-1) axis has been reported to modulate liver inflammation and progression to hepatocellular carcinoma (HCC) in patients with nonalcoholic fatty liver disease (NAFLD). Here, we examined whether the PDCD1 variation is associated with NAFLD severity in individuals with liver biopsy. Methods: We examined the impact of PDCD1 gene variants on HCC, as robust severe liver disease phenotype in UK Biobank participants. The strongest genetic association with the rs13023138 G>C variation was subsequently tested for association with liver damage in 2889 individuals who underwent liver biopsy for suspected nonalcoholic steatohepatitis (NASH). Hepatic transcriptome was examined by RNA-Seq in a subset of NAFLD individuals (n = 121). Transcriptomic and deconvolution analyses were performed to identify biological pathways modulated by the risk allele. Results: The rs13023138 C>G showed the most robust association with HCC in UK Biobank (p = 5.28E-4, OR = 1.32, 95% CI [1.1, 1.5]). In the liver biopsy cohort, rs13023138 G allele was independently associated with severe steatosis (OR 1.17, 95% CI 1.02-1.34; p = .01), NASH (OR 1.22, 95% CI 1.09-1.37; p C allele was linked to higher hepatic representation of M1 macrophages, paralleled by upregulation of pathways related to inflammation and higher expression of CXCR6. Conclusions: The PDCD1 rs13023138 G allele was associated with HCC development in the general population and with liver disease severity in patients at high risk of NASH.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results